Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley AcquisitionNews DeskJuly 16, 20260 Eli Lilly’s scope in neuroscience is broadening to psychedelics through a deal to buy AtaiBeckley, a clinical-stage company whose lead…